Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Benjamin Anderson MD, FACS
Benjamin O. Anderson MD, FACS Advisory Board
Sara Tolaney MD, MPH
Sara M. Tolaney MD, MPH Advisory Board
Elizabeth Smyth MD
Elizabeth Smyth MD Advisory Board
See All Experts
featured
Published in Oncology

Journal Scan / Research · November 01, 2018

Trifluridine/Tipiracil vs Placebo in Patients With Heavily Pretreated Metastatic Gastric Cancer

The Lancet Oncology

 

 Save  Recommend
 Share

Additional Info

Disclosure statements are available on the authors' profiles:

Axel Grothey MD

The Lancet Oncology
Trifluridine/Tipiracil Versus Placebo in Patients With Heavily Pretreated Metastatic Gastric Cancer (TAGS): A Randomised, Double-Blind, Placebo-Controlled, Phase 3 Trial
Lancet Oncol 2018 Oct 18;[EPub Ahead of Print], K Shitara, T Doi, M Dvorkin, W Mansoor, HT Arkenau, A Prokharau, M Alsina, M Ghidini, C Faustino, V Gorbunova, E Zhavrid, K Nishikawa, A Hosokawa, Ş Yalçın, K Fujitani, GD Beretta, EV Cutsem, RE Winkler, L Makris, DH Ilson, J Tabernero

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading

Recently Updated